BSE: 506197 | NSE: BLISSGVS | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Bliss GVS Pharma Ltd is a average quality company.
The key valuation ratios of Bliss GVS Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Bliss GVS Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 23.9% | 23.4% | 19.3% | 15.6% | 18.8% | 17.8% | 12% | 14.7% | 12.9% | 7.4% | - |
| Value Creation Index ⓘ | 0.7 | 0.7 | 0.4 | 0.1 | 0.3 | 0.3 | -0.1 | 0.1 | -0.1 | -0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 313 | 326 | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 | 657 |
| Sales YoY Gr. | - | 4.3% | 6.6% | -14.4% | 43.2% | 3.6% | 5.3% | 36.7% | -6% | 1.2% | - |
| Adj EPS ⓘ | 5.1 | 5.4 | 5.8 | 5.2 | 5.4 | 7 | 6 | 7.5 | 5.6 | 6.6 | 4.3 |
| YoY Gr. | - | 6.9% | 6.9% | -10.8% | 4.3% | 29.6% | -13.2% | 23.3% | -24.7% | 16.8% | - |
| BVPS (₹) ⓘ | 35.7 | 41.9 | 47.7 | 52.5 | 58.5 | 66.2 | 72.3 | 81.2 | 89.1 | 93.7 | 97.3 |
| Adj Net Profit ⓘ | 52.1 | 55.7 | 59.5 | 53.2 | 55.3 | 71.8 | 62.3 | 77.3 | 58.4 | 68.6 | 46 |
| Cash Flow from Ops. ⓘ | 15.4 | 59.6 | 38.5 | 22.7 | 48.3 | 63.2 | 67 | 114 | 43.8 | 126 | - |
| Debt/CF from Ops. ⓘ | 5.9 | 1.4 | 2 | 4.1 | 1.5 | 1.4 | 1.3 | 0.8 | 1.8 | 0.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 7.6% | 7.3% | 9.2% | 1.2% | ||||
| Adj EPS ⓘ | 2.9% | 4.1% | 2.7% | 16.8% | ||||
| BVPSⓘ | 11.3% | 9.9% | 9% | 5.1% | ||||
| Share Price | 7% | -1.5% | 8.4% | -7% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 15.3 | 13.9 | 12.9 | 10.3 | 9.7 | 11.2 | 8.7 | 9.6 | 6.5 | 7.1 | 4.6 |
| Op. Profit Mgn % ⓘ | 27.6 | 29.6 | 29 | 29.7 | 22.4 | 22.7 | 19.7 | 17.2 | 15.1 | 17.4 | 16.1 |
| Net Profit Mgn % ⓘ | 16.7 | 17.1 | 17.1 | 17.9 | 13 | 16.2 | 13.4 | 12.1 | 9.8 | 11.3 | 7 |
| Debt to Equity ⓘ | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 497 | 527 | 533 | 621 | 442 | 443 | 471 | 372 | 419 | 401 | 205 |
| Cash Conv. Cycle ⓘ | 154 | 206 | 206 | 270 | 269 | 307 | 293 | 212 | 233 | 242 | 170 |
Sales growth is good in last 4 quarters at 13.28%
Return on Equity has declined versus last 3 years average to 4.50%
Sales growth has been subdued in last 3 years 9.16%
Net Profit has been subdued in last 3 years 2.74%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 4.3 | 6 |
| TTM Sales (₹ Cr.) | 657 | 800 |
| BVPS (₹.) ⓘ | 97.3 | 95.9 |
| Reserves (₹ Cr.) ⓘ | 1,014 | 1,000 |
| P/BV ⓘ | 1.24 | 1.26 |
| PE ⓘ | 27.82 | 20.06 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 92.25 / 148.95 |
| All Time Low / High (₹) | 0.04 / 230.00 |
| Market Cap (₹ Cr.) | 1,272 |
| Equity (₹ Cr.) | 10.5 |
| Face Value (₹) | 1 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 313 | 326 | 348 | 298 | 427 | 442 | 466 | 636 | 598 | 605 |
| Operating Expenses ⓘ | 227 | 230 | 247 | 209 | 333 | 342 | 374 | 527 | 508 | 500 |
| Manufacturing Costs | 30 | 27 | 6 | 6 | 8 | 11 | 14 | 18 | 17 | 26 |
| Material Costs | 116 | 114 | 167 | 146 | 225 | 237 | 253 | 344 | 315 | 299 |
| Employee Cost | 17 | 22 | 25 | 26 | 34 | 44 | 59 | 65 | 73 | 83 |
| Other Costs ⓘ | 63 | 67 | 49 | 31 | 67 | 50 | 48 | 100 | 104 | 92 |
| Operating Profit ⓘ | 86 | 97 | 101 | 88 | 93 | 100 | 91 | 109 | 90 | 106 |
| Operating Profit Margin (%) | 27.5% | 29.6% | 28.9% | 29.7% | 21.8% | 22.7% | 19.6% | 17.2% | 15.1% | 17.4% |
| Other Income ⓘ | 21 | 23 | 9 | 11 | 36 | 37 | 19 | 33 | 51 | 35 |
| Interest ⓘ | 11 | 14 | 9 | 7 | 3 | 7 | 6 | 4 | 10 | 6 |
| Depreciation ⓘ | 5 | 6 | 6 | 6 | 6 | 9 | 14 | 14 | 15 | 24 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | -41 |
| Profit Before Tax ⓘ | 91 | 100 | 95 | 87 | 120 | 122 | 91 | 126 | 116 | 70 |
| Tax ⓘ | 31 | 35 | 36 | 30 | 46 | 29 | 24 | 34 | 30 | 20 |
| Profit After Tax | 60 | 66 | 59 | 57 | 74 | 92 | 68 | 93 | 85 | 51 |
| PAT Margin (%) | 19.2% | 20.1% | 17.0% | 19.1% | 17.4% | 20.9% | 14.5% | 14.6% | 14.3% | 8.4% |
| Adjusted EPS (₹) | 5.8 | 6.4 | 5.7 | 5.5 | 7.2 | 9.0 | 6.5 | 8.9 | 8.2 | 4.8 |
| Dividend Payout Ratio (%) | 12% | 8% | 10% | 18% | 14% | 6% | 8% | 6% | 6% | 10% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 368 | 432 | 492 | 541 | 603 | 683 | 746 | 841 | 928 | 981 |
| Share Capital ⓘ | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves ⓘ | 358 | 422 | 481 | 531 | 593 | 673 | 735 | 831 | 918 | 970 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 59 | 62 | 74 | 88 | 67 | 71 | 68 | 65 | 66 | 46 |
| Long Term Debt | 30 | 12 | 12 | 6 | 31 | 36 | 32 | 23 | 41 | 35 |
| Short Term Debt | 28 | 50 | 61 | 83 | 37 | 36 | 35 | 41 | 25 | 11 |
| Trade Payables | 50 | 35 | 64 | 35 | 31 | 56 | 67 | 84 | 76 | 54 |
| Others Liabilities ⓘ | 78 | 168 | 37 | 29 | 35 | 45 | 65 | 90 | 70 | 67 |
| Total Liabilities ⓘ | 555 | 697 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,148 |
Fixed Assets | ||||||||||
| Gross Block | 120 | 123 | 81 | 83 | 93 | 202 | 211 | 270 | 385 | 413 |
| Accumulated Depreciation | 38 | 44 | 6 | 11 | 15 | 23 | 37 | 45 | 60 | 84 |
| Net Fixed Assetsⓘ | 82 | 79 | 75 | 72 | 78 | 179 | 174 | 224 | 325 | 330 |
| CWIP ⓘ | 0 | 2 | 2 | 0 | 43 | 0 | 2 | 22 | 3 | 8 |
| Investmentsⓘ | 19 | 21 | 22 | 19 | 19 | 19 | 18 | 18 | 18 | 19 |
| Inventories | 23 | 22 | 28 | 40 | 55 | 61 | 84 | 90 | 74 | 89 |
| Trade Receivables | 211 | 251 | 239 | 283 | 342 | 405 | 349 | 409 | 399 | 400 |
| Cash Equivalents | 47 | 57 | 84 | 70 | 93 | 87 | 120 | 149 | 85 | 169 |
| Others Assetsⓘ | 174 | 266 | 216 | 209 | 105 | 105 | 199 | 167 | 236 | 134 |
| Total Assets ⓘ | 555 | 697 | 666 | 694 | 736 | 855 | 946 | 1,080 | 1,140 | 1,148 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 15 | 60 | 38 | 23 | 48 | 63 | 67 | 114 | 44 | 126 |
| PBT ⓘ | 91 | 100 | 95 | 87 | 120 | 122 | 91 | 124 | 116 | 111 |
| Adjustment ⓘ | 15 | 7 | 28 | 1 | 3 | 3 | 41 | 35 | 41 | 44 |
| Changes in Working Capital ⓘ | -51 | -28 | -47 | -29 | -26 | -30 | -43 | -14 | -76 | -0 |
| Tax Paid ⓘ | -40 | -20 | -37 | -36 | -50 | -32 | -23 | -30 | -38 | -29 |
| Cash Flow From Investing Activity ⓘ | -21 | -10 | -29 | 16 | -68 | -60 | -62 | -92 | -13 | -110 |
| Capex | -29 | -5 | -3 | -1 | -59 | -67 | -8 | -73 | -94 | -38 |
| Net Investments | 0 | -1 | -32 | 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| Others ⓘ | 7 | -3 | 5 | 14 | -9 | 7 | -54 | -22 | 81 | -71 |
| Cash Flow From Financing Activityⓘ | -31 | -35 | -15 | -22 | 9 | -6 | -12 | -13 | -26 | -21 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 24 | 13 | 2 | -5 | -16 | -10 |
| Interest Paid ⓘ | -10 | -11 | -9 | -8 | -3 | -4 | -6 | -2 | -6 | -5 |
| Dividend Paid ⓘ | -6 | -6 | -5 | -6 | -12 | -12 | -6 | -5 | -5 | -5 |
| Others ⓘ | -15 | -18 | 0 | -8 | 0 | -2 | -2 | -2 | -1 | -3 |
| Net Cash Flow ⓘ | -37 | 14 | -6 | 17 | -11 | -3 | -6 | 9 | 5 | -4 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 17.62 | 16.41 | 12.8 | 11.04 | 13 | 14.36 | 9.45 | 11.68 | 9.66 | 5.31 |
| ROCE (%) | 23.91 | 23.43 | 19.25 | 15.6 | 18.8 | 17.75 | 12.02 | 14.68 | 12.89 | 7.36 |
| Asset Turnover Ratio | 0.54 | 0.52 | 0.51 | 0.44 | 0.6 | 0.56 | 0.52 | 0.63 | 0.54 | 0.53 |
| PAT to CFO Conversion(x) | 0.25 | 0.91 | 0.64 | 0.4 | 0.65 | 0.68 | 0.99 | 1.23 | 0.52 | 2.47 | Working Capital Days |
| Receivable Days | 228 | 257 | 255 | 319 | 267 | 308 | 295 | 217 | 246 | 241 |
| Inventory Days | 25 | 25 | 26 | 42 | 40 | 48 | 57 | 50 | 50 | 49 |
| Payable Days | 172 | 136 | 108 | 124 | 54 | 67 | 88 | 80 | 93 | 79 |
Bliss Gvs Pharma Limited was incorporated on December 11, 1984, as Public Limited Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company has established a foothold in various therapeutic categories including anti-malarial, anti-fungal, contraceptive, laxative, anti-haemorrhoidal, anti-spasmodic, anti-biotic, anti-microbial, antiinflammatory, anti-pyretic, analgesic, and several others.
It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Over the last decade, it has acquired definitive know-how in other dosage forms & therapeutic segments, which is exemplified by its ever-expanding product offering across more than sixty countries. With significant expansion in R & D, Manufacturing & Marketing capabilities, the company is poised for an accelerated rate of growth which makes for very exciting times at Bliss GVS.
Business area of the company
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company’s most unique product is ‘Today Vaginal Contraceptive’, a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.
Key Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
